AU2018262698B2 - Expansion of gamma delta T cells, compositions, and methods of use thereof - Google Patents

Expansion of gamma delta T cells, compositions, and methods of use thereof Download PDF

Info

Publication number
AU2018262698B2
AU2018262698B2 AU2018262698A AU2018262698A AU2018262698B2 AU 2018262698 B2 AU2018262698 B2 AU 2018262698B2 AU 2018262698 A AU2018262698 A AU 2018262698A AU 2018262698 A AU2018262698 A AU 2018262698A AU 2018262698 B2 AU2018262698 B2 AU 2018262698B2
Authority
AU
Australia
Prior art keywords
cells
population
expanded
cell
haematopoietic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018262698A
Other languages
English (en)
Other versions
AU2018262698A1 (en
Inventor
Richard Beatson
Adrian HAYDAY
Maria Luisa IANNITTO
Natalie MOUNT
Oliver Nussbaumer
Richard Woolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
GammaDelta Therapeutics Ltd
Original Assignee
Kings College London
GammaDelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London, GammaDelta Therapeutics Ltd filed Critical Kings College London
Publication of AU2018262698A1 publication Critical patent/AU2018262698A1/en
Application granted granted Critical
Publication of AU2018262698B2 publication Critical patent/AU2018262698B2/en
Priority to AU2025230679A priority Critical patent/AU2025230679A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2309—Interleukin-9 (IL-9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2333—Interleukin-33 (IL-33)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018262698A 2017-05-03 2018-05-03 Expansion of gamma delta T cells, compositions, and methods of use thereof Active AU2018262698B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025230679A AU2025230679A1 (en) 2017-05-03 2025-09-10 Expansion of gamma delta T cells, compositions, and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1707048.3A GB201707048D0 (en) 2017-05-03 2017-05-03 Expansion of gamma delta cells, compositions, and methods of use thereof
GB1707048.3 2017-05-03
PCT/EP2018/061413 WO2018202808A2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta t cells, compositions, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025230679A Division AU2025230679A1 (en) 2017-05-03 2025-09-10 Expansion of gamma delta T cells, compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2018262698A1 AU2018262698A1 (en) 2019-12-12
AU2018262698B2 true AU2018262698B2 (en) 2025-07-03

Family

ID=59010925

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018262698A Active AU2018262698B2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta T cells, compositions, and methods of use thereof
AU2025230679A Pending AU2025230679A1 (en) 2017-05-03 2025-09-10 Expansion of gamma delta T cells, compositions, and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025230679A Pending AU2025230679A1 (en) 2017-05-03 2025-09-10 Expansion of gamma delta T cells, compositions, and methods of use thereof

Country Status (14)

Country Link
US (2) US11655453B2 (https=)
EP (1) EP3619298A2 (https=)
JP (3) JP2020518289A (https=)
KR (2) KR102812405B1 (https=)
CN (1) CN110914410A (https=)
AU (2) AU2018262698B2 (https=)
BR (1) BR112019023076A2 (https=)
CA (1) CA3062386A1 (https=)
EA (1) EA201992610A1 (https=)
GB (1) GB201707048D0 (https=)
IL (3) IL270365B2 (https=)
MX (2) MX2019013001A (https=)
PH (1) PH12019502485A1 (https=)
WO (1) WO2018202808A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
GB201818243D0 (en) * 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
KR20210111746A (ko) 2018-11-08 2021-09-13 감마델타 테라퓨틱스 리미티드 세포를 단리 및 증식하는 방법
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
GB201909144D0 (en) * 2019-06-25 2019-08-07 Autolus Ltd Culture medium
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
JP2023504185A (ja) * 2019-12-03 2023-02-01 アディセット バイオ， インコーポレイテッド γδＴ細胞集団を多価薬剤で増殖させるための方法及びその組成物
US20210290674A1 (en) * 2020-03-20 2021-09-23 GammaDelta Therapeutics Ltd. Methods for treating myeloid malignancies
KR20230013022A (ko) 2020-03-20 2023-01-26 감마델타 테라퓨틱스 엘티디 골수성 악성종양의 치료를 위한 v 델타1+ t 세포
GB202006989D0 (en) 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
GB202013962D0 (en) * 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
CN113234675A (zh) * 2021-03-31 2021-08-10 广西医科大学 一种γδT细胞以及采用体外制备γδT细胞的方法
GB202105113D0 (en) 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
US20240197876A1 (en) * 2021-04-14 2024-06-20 The Trustees Of The University Of Pennsylvania Methods to determine treatment efficacy with gamma-delta t cells
IL307757A (en) * 2021-04-16 2023-12-01 Acepodia Biotechnologies Ltd Novel compositions approved in gamma delta T cells, methods of preparation, and uses thereof
JP2024539088A (ja) * 2021-10-20 2024-10-28 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍浸潤ガンマ－デルタｔ細胞を拡大するための方法及び材料
KR20240130130A (ko) * 2022-01-05 2024-08-28 인히브릭스 바이오사이언스, 인크. 감마 델타 t 세포 결합 폴리펩티드 및 그의 용도
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
EP4687923A1 (en) 2023-04-07 2026-02-11 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
WO2025017531A1 (en) 2023-07-20 2025-01-23 Takeda Pharmaceutical Company Limited Grid-free methods for making gamma delta t cells
IL326116A (en) * 2023-07-26 2026-03-01 Janssen Biotech Inc Materials and methods for cell culture

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015189356A1 (en) * 2014-06-11 2015-12-17 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
WO2016198480A1 (en) * 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6537812B1 (en) 1998-11-04 2003-03-25 Hemosol Inc. Methods for the production of TcRγδ+ T cells
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
AU2006340750B2 (en) 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
CN103635573B (zh) 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
ES2539845B1 (es) 2013-08-05 2016-04-13 Universidad De Alicante Procedimiento y síntesis de monolitos de carbón activo a partir de cascarilla de cacao
JP2016539929A (ja) * 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
WO2016164705A1 (en) * 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
EP4148124A1 (en) 2015-10-30 2023-03-15 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015189356A1 (en) * 2014-06-11 2015-12-17 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
WO2016198480A1 (en) * 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHING-LIANG CHU ET AL: "Differential Effects of IL-2 and IL-15 on the Death and Survival of Activated TCRgd1 Intestinal Intraepithelial Lymphocytes1", THE JOURNAL OF IMMUNOLOGY, 15 February 1999 (1999-02-15), pages 1896 - 1903 *
V. CHENNUPATI ET AL: "Intra- and Intercompartmental Movement of T Cells", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 9, 24 September 2010 (2010-09-24), pages 5160 - 5168 *
WOOLF RICHARD ET AL: "Potential for innate-like responsiveness of resident T cells in human skin: a new perspective on tissue immune-surveillance", THE LANCET (LETTERS TO THE EDITOR), vol. 387, 25 February 2016 (2016-02-25), pages 108 - 108 *

Also Published As

Publication number Publication date
IL312633A (en) 2024-07-01
US11655453B2 (en) 2023-05-23
IL270365B1 (en) 2024-06-01
CN110914410A (zh) 2020-03-24
BR112019023076A2 (pt) 2020-06-09
IL312633B2 (en) 2025-08-01
AU2025230679A1 (en) 2025-10-02
WO2018202808A2 (en) 2018-11-08
GB201707048D0 (en) 2017-06-14
WO2018202808A9 (en) 2019-03-07
US20230242878A1 (en) 2023-08-03
AU2018262698A1 (en) 2019-12-12
EA201992610A1 (ru) 2020-04-23
IL270365A (https=) 2019-12-31
MX2024004897A (es) 2024-05-07
WO2018202808A3 (en) 2019-01-03
JP2025134795A (ja) 2025-09-17
CA3062386A1 (en) 2018-11-08
US20210087528A1 (en) 2021-03-25
KR102812405B1 (ko) 2025-05-23
IL312633B1 (en) 2025-04-01
US12458698B2 (en) 2025-11-04
PH12019502485A1 (en) 2021-01-04
KR20250080907A (ko) 2025-06-05
JP7698672B2 (ja) 2025-06-25
JP2020518289A (ja) 2020-06-25
KR20200024770A (ko) 2020-03-09
MX2019013001A (es) 2021-01-20
EP3619298A2 (en) 2020-03-11
IL270365B2 (en) 2024-10-01
IL319114A (en) 2025-04-01
JP2023058687A (ja) 2023-04-25

Similar Documents

Publication Publication Date Title
AU2018262698B2 (en) Expansion of gamma delta T cells, compositions, and methods of use thereof
US20230099491A1 (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
HK40090397A (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
BR122025001918A2 (pt) Métodos de expansão de células t gama delta, composições, seu uso e uso de células t gama delta expandidas
EA049808B1 (ru) ЭКСПАНСИЯ γΔ-Т-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA044224B1 (ru) ЭКСПАНСИЯ γδ-T-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK1253954B (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)